share_log

Femasys | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SEC announcement ·  Apr 5 17:10
Summary by Moomoo AI
Femasys Inc., a medical technology company based in Suwanee, Georgia, has filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on April 5, 2024, to register additional shares for its employee incentive programs. The filing, under Form S-8, pertains to the registration of 866,295 additional shares of common stock under the Femasys Inc. 2021 Equity Incentive Plan and 216,573 additional shares under the Femasys Inc. Employee Stock Purchase Plan. These registrations are in accordance with the automatic increase provisions of the respective plans. The company, which is categorized as a non-accelerated filer, a smaller reporting company, and an emerging growth company, has also incorporated by reference the contents of its previous registration statements filed in 2021 and 2023. Kathy Lee-Sepsick, President and CEO, signed the Registration Statement, which includes legal opinions and consents from Dechert LLP and KPMG LLP.
Femasys Inc., a medical technology company based in Suwanee, Georgia, has filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on April 5, 2024, to register additional shares for its employee incentive programs. The filing, under Form S-8, pertains to the registration of 866,295 additional shares of common stock under the Femasys Inc. 2021 Equity Incentive Plan and 216,573 additional shares under the Femasys Inc. Employee Stock Purchase Plan. These registrations are in accordance with the automatic increase provisions of the respective plans. The company, which is categorized as a non-accelerated filer, a smaller reporting company, and an emerging growth company, has also incorporated by reference the contents of its previous registration statements filed in 2021 and 2023. Kathy Lee-Sepsick, President and CEO, signed the Registration Statement, which includes legal opinions and consents from Dechert LLP and KPMG LLP.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more